Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center
Our findings suggest that NHA therapy may confer reduced survival benefits in mCRPC patients with ECOG PS ≥2. While hope for NHA treatment persists, particularly given its oral administration and tolerability, careful consideration and discussion with patients regarding treatment expectations and palliative care goals are warranted in this challenging patient population.
Authors
- Philipp Krausewitz (ORCID: https://orcid.org/0000-0002-8213-9975)
- Thomas Büttner (ORCID: https://orcid.org/0000-0003-0316-9621)
- Stefan Hauser (ORCID: https://orcid.org/0000-0002-1022-7482)
- Philipp Lossin
- Stefan Latz
- Carolin Jacobs
Institutions
- University Hospital Bonn (DE)
Publication Details
- Journal
- Aging Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/agm2.12372
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00